Thaysen stepped in to lead Illumina through a tumultuous time, and now—as this GEN interview relates—he is carrying out his near- and long-term plans for the company.
Biomanufacturers can avoid downstream detours if they are guided less by trial and error, and more by machine learning.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback